Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice Tsang Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017

Cited by 567 works. doi:10.1016/s1470-2045(17)30339-x

Authors

References